The Board of Directors of Glenmark Life Sciences Limited at its meeting held on November 10, 2021, has, inter alia, considered and approved:<BR> Financial Result:<BR> 1. The Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.<BR> The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also<BR> being made available on the website of the Company at www.glenmarkllfesciences.com<BR> Interim Dividend:<BR> 2. Declared an interim dividend of Rs. 10.5/-per equity share of face value of Rs.2/ each for the financial year ending 31st March, 2022. Record date for the purpose of determining<BR> the entitlement of the shareholders for the interim dividend has been fixed as 23rd, November 2021, and dividend will be paid to the shareholders on or after 3rd December, 2021.
|